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ABSTRACT
Objective: Modern medicine needs to shift from a wait and react, curative discipline to a preventative,
interdisciplinary science aiming at providing personalised, systemic and precise treatment plans to
patients. The aim of this work is to present how the integration of machine learning approaches
with mechanistic computational modelling could yield a reliable infrastructure to run probabilistic
simulations where the entire organism is considered as a whole.
Methods: We propose a general framework that composes advanced AI approaches and integrates
mathematical modelling in order to provide a panoramic view over current and future physiological
conditions. The proposed architecture is based on a graph neural network (GNNs) forecasting
clinically relevant endpoints (such as blood pressure) and a generative adversarial network (GANs)
providing a proof of concept of transcriptomic integrability.
Results: We show the results of the investigation of pathological effects of overexpression of ACE2
across different signalling pathways in multiple tissues on cardiovascular functions. We provide a
proof of concept of integrating a large set of composable clinical models using molecular data to
drive local and global clinical parameters and derive future trajectories representing the evolution of
the physiological state of the patient.
Significance: We argue that the graph representation of a computational patient has potential to solve
important technological challenges in integrating multiscale computational modelling with AI. We
believe that this work represents a step forward towards a healthcare digital twin.
Keywords Precision medicine · Graph representation · Generative adversarial networks
1 Introduction
Large part of humanity cannot afford basic medical care. Where medicine has reached high level of biological and
engineering technological complexity, costs have grown so much to reduce the access to a substantial percentage of the
population. The target is very clear: we need healthcare to be precise and personalised at a reduced cost per capita in
order to have 100% access [1]. A meaningful way to reach this target is to design a precise and predictive medicine.
Precision will require the integration of large amount of observations at individual and other observations at population
levels. These measures will be taken at different scales, from genome to clinical and family history and at systemic
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levels, i.e. considering multiple tissues and organs. We have no capacity to integrate such disparate information into
equation-based models but we can use machine learning and, in particular, deep learning methods, to achieve this
integration goal. The predictive capability will allow us to shift from a wait and react, curative modus to a proactive
modus of maintaining of the well-being condition or reverse disease status before more damage spreading (emergence
of comorbidities and frailty).
Precision and predictable properties will therefore implicitly include personalised and preventative properties. The
predictive capacity would act in lowering the overall and general cost of healthcare if the data integration step (leading
to precision) would come at no extra cost. We believe that recent graph representation approaches [2] could scale across
all the variety of body signals at different levels and could sum all the above mentioned properties making possible a
revolution in healthcare.
The development of reliable systems accurately forecasting physiological conditions of patients is one of the primary
objectives of precision medicine [3]. The underlying complexity of human physiology makes this research field
extremely challenging [4, 5]. On one side, such complexity requires the development of models with very high capacity.
On the other hand, the internal activity of several physiological systems are actually independent from others. For
instance, the periodic contraction myocardiocytes does not depend on the pancreatic release of insulin. Nay, the
mutual influence of several physiological processes is not hard-coded in their behaviour, but it is usually carried out
by specialised transmitters, generating sophisticated signalling pathways. Besides, such signals can be transmitted
from micro to macroscale systems and vice versa, affecting the whole organism at different levels [6, 7]. From a
computational perspective, this means that each biological system could be modelled independently in the first place,
provided that it receives expected signals from other systems [8].
This work proposes a new class of black-box machine-learning assisted methods for model analysis that scale to medical
device deployment and run time monitoring and verification. By fusing ideas from systems medicine with scientific
computing and machine learning we have developed a software that integrates and automates the analysis of vital
parameters models under large uncertainty. A high degree of automation could transform how we use models in the
scientific and medical discovery cycle and open up for a next-generation of powerful medical devices for probing the
inner workings of full body in well-being and disease conditions.
The proposed architecture combines the qualities of a generative model [9] with a graph-based representation [10] of
pathophysiological conditions (see Figure 1). On one side, the generative model can be used to produce synthetic data
under different biological states that might not even be observed in reality. By augmenting the set of explorable states of
the underlying biological system, the generative model may be employed for the simulation of extremely rare clinical
scenarios representing precarious conditions which might be difficult to analyse otherwise [11]. In clinical contexts,
this means that physicians will be able to set up personalised experiments in a virtual environment representing their
patients in a very detailed and realistic way. On the other side, the graph model represents a virtual prototype of patients,
a sort of "digital twin" mirroring the actual multiscale biological system [12], thus providing a general and flexible
framework to run probabilistic simulations. The intrinsic characteristics of graph models make them suitable for the
analysis of complex systems, while still providing highly interpretable results [13]. Graph are not just interpretable, but
the network itself can be induced from data or even handcrafted. Researchers may take advantage of generative models
for graphs to find optimal network configurations [14] or formalise mathematical properties in form of differential
equations or logical constraints with the purpose of describing the underlying system [15]. A panoramic view of
individuals’ conditions is provided by the final network configuration which combines information at organ, tissue, and
cellular level. Cross-modal signals are also supported by the most recent graph learning frameworks, thus allowing the
combination of different data sources, both structured and unstructured, real or simulated by generative methods. By
relying upon flexible and modular architectures, our "digital twin" model can be conveniently deployed in dedicated
hardware modules which might also be composed in a hierarchical fashion according to clinical needs.
2 Design of a biomedical Digital Twin
The birth of the term "digital twin" could be the NASA’s Apollo program where one spacecraft was launched into the
outer space, while a "twin" spacecraft remained on earth to mirror flight conditions. Digital twin has been defined
as “an integrated multiphysics, multiscale, probabilistic simulation of a vehicle or system that uses the best available
physical models, sensor updates, fleet history, etc., to mirror the life of its flying twin” [16, 17]. The Digital twin is
a virtual prototype; the analysis of its digital life cycle provides information to understand a product’s functionality,
manufacturing, behaviour and usage prior to building it. Here the meaning of digital twin is slightly different: there
is no product to be built, instead experimenting therapies on a digital twin will be cost effective and will provide
us best practice to be used on the biological twin. Here an artificial intelligence model could enable the prediction
of disease trajectories before the insurgence of symptoms. The personal medical digital twin could also represent a
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pragmatic way for the cyber-physical fusion, as a new approach to support biomedical engineering design. In our vision
a composable AI architecture could enable the development of automatic analysis and verification techniques that are
key to translational medicine.
This work proposes a modular approach which can be used to model the evolution of pathophysiological conditions.
The first module is based on a graph neural network (GNNs) forecasting clinically relevant endpoints (such as blood
pressure) while the second one is represented by a generative adversarial network (GANs) providing a proof of concept
of omic integrability. For experimental simulations we use and expand a clinical case study presented in [18] as a
reference. In [18], authors introduced a handcrafted dynamical system of equations representing some of the main
physiological processes involved in cardiovascular and infection diseases. The computational model was developed to
simulate systemic ripple effects caused by viral infections targeting the renin-angiotensin-aldosterone system (RAS)
in patients with comorbid conditions. In such a context, the most relevant endpoints requiring constant monitoring
include blood pressure, oxygenation, and insulin levels (for diabetic patients). In patients with multi-factorial diseases a
very large set of factors may cause an irreparable impairment of such a delicate physiological equilibrium. Genomic
traits, ageing, therapies, and lifestyle routines like physical exercise or dietary habits may all have an impact on keeping
patients in a healthy state. Recording and keeping track of the stratification of all such factors is problematic by itself,
but it is critical to get the whole picture. However, the actual challenge consists in exploiting the acquired information
to forecast the evolution of clinical endpoints over time. Depending on clinical needs and patient’s comorbidities, it
may be worth accounting for just a subset of such endpoints. Thus a sparse modelling approach whose components can
be combined or activated on the fly may have a great potential in clinical practice.
2.1 The effectiveness of GNNs and GANs in biomedical signal analysis
Several properties of graph and generative adversarial neural networks make them suitable for medical data analysis:
• Non-linearity: detection of non linear patterns is of key interest as most systems are inherently nonlinear in
nature. Examples in medicine include heart rate dynamics, pulmonary functions, vascular structure, and gait
dynamics. There is often a loss of non linearity and multiscale fractal in ageing and disease conditions [19].
• Interpretability: the possibility of interpreting the behaviour of models and the reason for their predictions
is pivotal if not critical for in many fields including clinical practice. Thanks to their structure, graph-based
models are much easier to interpret with respect to other neural approaches.
• Non-Euclidean geometry: tissue and organ distributions could be modelled as graph models where each
node or the graph contain time-dependent signals; similarly for pressure and electric sensors positioned at
various parts of the body.Lymphatic vessels can also be modelled as a network where lymph nodes are vertices.
At lower scale, cell arrangements in tissues form particular manifolds; proteins and genes are organised in
regulatory networks; other examples are cytoskeleton and organelles (mitochondria networks). Additionally,
diseases could be seen as nodes in a graph where edges represent comorbidity or underlying polygenic causes.
• Modularity: A key property of GNNs is modularity, which allows to learn independent mechanisms that can be
reused in several parts of the graph. Modularity facilitates scalability and allows to model dynamic properties
of graphs.
• Cross-modality: both GNNs and GANs can learn how to combine structured and unstructured data sources,
spanning different levels of biological complexity. This is particularly relevant when integrating signals at
different levels of biological scale such as DNA methylation and fMRI data.
• Generative: both GNNs and GANs can learn how to generate new data preserving the statistical properties
of the training set. This could be used to compare statistics at individual level with those at specific groups
identified with stratification analysis or at general population levels.
• Multiscale: the graph representation has the capability of integrating granular information organised as
networks at different layers of biological complexity. This allows to recognise patterns in higher-order
structures such as motifs, pathways, tissues (as compositions of cells), organs (as composition of tissues),
processes and apparatus (as composition of organs), stratification (as composition of individuals).
• Spectral density: together with spatial properties, GNN are amenable to frequency domain analysis. This
allows to investigate network motifs, substructures and periodical patterns at network levels.
2.2 Graph neural model
Graphs are mathematical structures which are used to model a set of objects (nodes) and their mutual relationships
(edges) [20]. Graphs are employed in a variety of research areas as they provide a general and flexible data structure for
3
A PREPRINT - SEPTEMBER 18, 2020
modelling real-world systems [21, 22, 23, 24]. Graph neural networks (GNN) are deep learning-based models working
on the graph domain [10, 25, 26]. Their properties have been recently drawn the attention of the artificial intelligence
research community given their high interpretability and as the only non-Euclidean models available in machine learning
[27, 13]. The combination of graph theory and neural network elements have made GNNs one of the most promising
tools to analyse complex systems in the graph domain. From neural networks GNNs inherit a data-driven approach
associated with a multi-layer architecture, which is the key to extract hierarchical patterns from data. However, unlike
other deep-learning models, GNNs exploit additional features from graph theory and other mathematical disciplines.
The main advantage with respect to other machine learning models relies in their extremely flexible and interpretable
architecture. Once defined, the main endpoints of a system together with their mutual relationships directly induce
a corresponding graph representation, which can be easily interpreted from a human standpoint. The abstract graph
representation can be handcrafted, when the complexity of the underlying system allows it, or even automatically
induced from data using generative approaches [14]. Hybrid techniques may also be explored taking advantage of
generative algorithms for handling system complexity and human modelling to customise the most relevant endpoints.
The design of GNNs is based on two basic principles, flexibility and composability. GNNs support different graph
structures as well as flexible representations of global, node, and edge attributes, customizable according to specific
demands of tasks.
2.2.1 Graph network blocks
The GNN framework proposed by Battaglia et al. [25] is based on modules called graph network blocks (GN blocks)
representing the core computation units of a GNN. Multiple GN blocks can be composed or even combined with other
neural networks to generate complex architectures. A graph neural network can be defined as a 3-tuple G = (u, H,E).
H = {hi}i=1:Nv is the node set where the feature of each node is denoted by hi. E = {(ek, rk, sk)} is the edge set
where each node is represented by its features ek, the receiver node rk, and the sender node sk. u denotes a set of global
attributes representing the state of the underlying system. Each GN block consists of three update functions, φ, and
three aggregation functions, ρ:
e′k = φ
e(ek,hrk ,hsk ,u) e¯
′
i = ρ
e→h(E′i)
h′i = φ
h(e¯k,hi,u) e¯′ = ρe→u(E′) (1)
u′ = φu(e′,h′,u) h¯′ = ρh→u(H ′)
where E′i = {(e′k, rk, sk)}, H ′ = {(h′i)}i=1:Nv , and E′ =
⋃
iE
′
i = {(e′k, rk, sk)}k=1:Ne . In order to train a GN block
in full, six computation steps are required, alternating the update and aggregation functions. For each edge, E′i is
computed through the update function φe. The result is then aggregated by means of the function ρe→v . The output e¯′i
corresponds to an edge update and it is employed to update node representations h′i by means of φh. ρe→u and ρh→u
perform aggregation steps generating e¯′ and h¯′ from edge and node updates, respectively. Global attributes represented
by u′ are computed leveraging the information from e¯′, h¯′, and u via the function φu. The learning process of each GN
block may be independent or co-dependent with other blocks. Constraints may apply on edges, information flows, or
global attributes, depending on the application. In this work we are just interested in the evaluation of global attributes
to monitor clinical endpoints and we did not apply any learning constraint, even if in clinical practice may still be of
great interest. Given a set of labels for global attributes t = {ti}i=1:Nv and the corresponding predictions provided by
the GN block û′ = {û′i}i=1:Nv representing the evolution of the underlying biological system, we aim at minimising
the following objective function:
min
θ
Nv∑
i=1
(
ti − û′i
)
(2)
where θ is the set of model’s parameters.
2.2.2 Graph layers
GNNs natively allow the design of complex systems using a modular approach. First, the complexity is broken up by
developing independent subsystems representing genomic alterations, biological pathways, and organ physiology. Each
subsystem can be represented as a different node or set of nodes in a GNN, while inter-process signals can be reframed
as message passing operations supporting multiscale ripple effects. Homogeneous subsystems can be aggregated into
layers according to their characteristics. Our digital patient model is composed of four layers: the transcriptomic layer,
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y(n) = F(t,y,y′, . . . ,y(n−1))
ODE system
patient
t
healthy trajectory
disease
φe
φh
ρe→h
φe
ρh→u
G
h1 h2 . . . hnH
E1 E2 . . . EkE
h′1 h
′
2
. . . h′n H′
u′1 u
′
2
. . . u′n U′
z1 z2 . . . zu q1 . . . qc
r1 . . . rk
Concat∥∥ e1 . . . ec EmbedWGj q¯j
. . .
. . .
. . .
m1 m2 . . . mn Mask
mG
x1 x2 . . . xn xˆ1 xˆ2 . . . xˆn
Concat∥∥ e1 . . . ec EmbedWDj q¯j
. . .
. . .
y¯ . . .
z q
r
eG
xˆ
m
x
eD
Generator
Critic
Message passing graph neural network
Figure 1: Architecture of the digital twin model. The generator receives a noise vector z, and categorical (e.g. tissue
type; q) and numerical (e.g. age; r) covariates, and outputs a vector of synthetic data (xˆ). The critic receives data
from two input streams (real, blue; and synthetic, red), a mask m indicating which components of the input vector are
missing, and the numerical r and categorical q covariates. The critic produces an unbounded scalar y¯ that quantifies the
degree of realism of the input samples from the two input streams. The handcrafted ODE system proposed in [18] is
used to determine a graph representation of patient’s physiology. The message passing neural network updates latent
node features to estimate global attributes describing the evolution of the underlying physiological system.
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the cellular layer, the organ layer, and the exposomic layer. Other layers that bring information on other omics or body
sensor network i.e. a collection of networked sensors that can be used to monitor human physiological signals, could be
similarly implemented.
Transcriptomic layer The transcriptomic layer operates on the set of RNA transcripts produced by the genome at
a particular time. Currently, RNA sequencing (RNA-seq) can measure RNA abundance across the entire genome
with high resolution. The resulting high-throughput gene expression data can be used to uncover disease mechanisms
[28, 29, 30], propose novel drug targets [31, 32], provide a basis for comparative genomics [33], and address a wide
range of fundamental biological problems.
In this work, we study the crosstalk between tissues in the organ layer (see Figure 1) through the communicome, e.g.
communication factors in blood [34]. Specifically, we analyse to what extent the expression of genes involved in the
renin-angiotensin system can be explained by genes from signalling and receptor pathways, including the chemokine,
TNF, and TGF-β pathways. We further develop a transcriptomics generative model based on a generative adversarial
network [35] and simulate the effects of SARS-CoV-2 infection by conditioning on high expression of ACE2 in the
lung, kidney, and pancreas.
Cellular layer The cellular layer involves biological processes affecting individual cells from metabolism and protein
synthesis to replication and motility. In this study we focus on modelling the Renin-Angiotensin System (RAS), one
of the main biological pathways regulating blood pressure and closely related to SARS-CoV-2 infectivity. Hence, it
represents a suitable case study to demonstrate the flexibility and expressiveness of our GNN-based approach. The
renin-angiotensin system is a hormone system regulating vasoconstriction and inflammatory response [36]. The key
hormone of the system is the peptide Angiotensin II (ANG-II) generated from the decapeptide Angiotensin I by the
angiotensin-converting enzyme (ACE). ANG II promotes vasoconstriction, hypertension, inflammation, and fibrosis
by activating the ANG-II type 1 receptor (AT1R) [37, 38]. Glucose concentration, ACE inhibitor treatments, and
viral infections binding to ACE2, such as SARS-CoV-2, can all have a significant impact on the RAS. A high glucose
concentration may determine chronic hypertensive conditions. Reducing ANG II production with ACE inhibitors
increases vasodilation and vasoprotection effects stimulated by the overproduction of AT2R and ANG-(1-7) [39]. Viral
infections such as SARS-CoV-2 may also have an impact on RAS, as the virus binds to ACE2 in order to gain entry
into the host cell. This results in an altered ACE2 activity and concentration, possibly leading to hypertension and
inflammatory response [40].
Organ layer The organ layer comprises group of tissues with similar functions (organs) and complex networks of
cooperating organs. Given the nature of the multi-factorial disease under study, we limited the organ layer to the
circulatory system and a physiological representation of a few organs [18]: heart, lungs, and kidneys. The heart model
includes four compartments known as chambers [41]. Deoxygenated blood collected from the superior and inferior
venae cavae flows into the right atrium. When the right atrium contracts, the blood is pumped through the tricuspid valve
into the right ventricle. From the right ventricle the blood is pumped into the pulmonary trunk through the pulmonary
valve flowing towards the lungs where carbon dioxide is exchanged for oxygen. The pulmonary circulation is composed
of five vascular segments: proximal and distal pulmonary artery, small arteries, capillaries, and veins. Oxygenated
blood collects into the left atrium via the pulmonary veins. From there, it flows into the left ventricle through the mitral
valve and it is pumped into the aorta through the aortic valve for systemic circulation, providing oxygen and nutrients
to body cells for metabolism in exchange for carbon dioxide and waste products. The mean arterial blood pressure is
controlled by baroreceptors, special sensory neurons excited by a stretch in the carotid sinus and aortic arch vessels.
They relay sensory information regarding blood pressure changes to the central nervous system where it is processed
and utilised primarily in autonomic reflexes, regulating short-term blood pressure.
Exposomic layer The exposome refers to the totality of exposure individuals experience from conception until death
and its impact on chronic and acute diseases [42]. Toxicants, dietary regimens, treatments, physical exercise, posture,
lifestyle habits, all of them are possible exposures taking part to individual’s well-being or disease condition. All such
environmental factors are deeply coupled among themselves but also with individuals influencing the effects of new or
present exposures. The exposome is intrinsically co-dependent on a person’s genetics, epigenetics, health status, and
physiology. For instance, regular exposure to pollution may lead to the outbreak of a lung carcinoma which in turn
may call for clinical intervention. In this work, we consider four types of exposures: dietary habits, physical activity,
therapeutic treatments, and viral infections.
2.2.3 Inter-process signals and clinical endpoints
One of the main advantages of using GNN-based models relies in that inter-process and multiscale communications
can be natively implemented using message passing. In a GNN, each biological entity can be represented as a node
6
A PREPRINT - SEPTEMBER 18, 2020
while the relationship between two entities can be modeled using directional edges. Signals exchanged between nodes
are implemented using message functions φh (see Eq. 1) which are used to update the hidden states of nodes. Such
state transition will then have an impact on messages exchanged at the following time steps. Another strength of
GNN models consists in the possibility of supervising the evolution of the underlying system, by using the readout
functions φu. Hence, the endpoints of multi-factorial diseases can be directly controlled by checking the output of
readout functions in critical nodes. The resulting GNN model will combine a simple and modular design with a versatile
structure accommodating for complex multiscale systems where clinical endpoints can be easily monitored and forecast
in real time.
2.2.4 Assessing prediction uncertainty
The aim of developing a digital patient model is to provide an accurate estimation of the trajectory of a patient by
forecasting clinically relevant endpoints. In such a context, quantifying model uncertainty is critical. One of the most
established techniques relies upon the use of dropout [43] at test time, as a Bayesian approximation, without sacrificing
either computational complexity or test performance [44]. In this framework, the first two moments of the predictive
distribution q performing T stochastic forward passes for a sample x∗ with label y∗ can be estimated as [45]:
Eq(y∗,x∗)(y∗) ≈ 1
T
T∑
i=1
ŷ∗(x∗,W t1 , . . . ,W
t
L) (3)
Varq(y∗,x∗)(y∗) ≈ τ−1ID + 1
T
T∑
i=1
ŷ∗(x∗,W t1 , . . . ,W
t
L)
T ŷ∗(x∗,W t1 , . . . ,W
t
L)
− Eq(y∗,x∗)(y∗)TEq(y∗,x∗)(y∗) (4)
where ŷ∗ is the predicted label, {Wi}Li=1 is a set of random variables representing the weights of a neural network
with L layers, ID is an identity matrix, D is the number of output units of the neural network, and τ is a precision
hyper-parameter. The method has also been generalised to convolutional [46] and recurrent networks [47].
Here we show how such technique can be used to quantify the uncertainty of a GNN by generating a predictive
distribution of the trajectories representing the future states of the patient. Let x∗1, . . . , x
∗
k be a sequence of real values
representing a clinical endpoint measured at 1, . . . , k time steps. Let f t be a stochastic model which takes a sequence
x∗1, . . . , x
∗
k as input and it outputs a prediction ŷ
∗ ∈ R. We are interested in estimating a predictive distribution of the
trajectories of the variable x over the next k+ 1, . . . , k+ h time steps. To this aim, we can use an iterative algorithm by
generating one trajectory at a time. The first prediction ŷ∗k+1 can be generated as:
ŷ∗,tk+1 = f
t(x∗1, . . . , x
∗
k) (5)
By using the obtained prediction and sliding the time window one time step further, we can generate the first prediction
for the second time step k + 2:
ŷ∗,tk+2 = f
t(x∗2, . . . , x
∗
k, ŷ
∗,t
k+1) (6)
The procedure can be repeated for k + h time steps to generate a single trajectory. Model uncertainty can be assessed
building multiple trajectories by performing T stochastic forward passes. The resulting algorithm is equivalent to a
Monte Carlo sampling as proven by Gal et al. [44]. In our GNN model, the approach we just described can be easily
applied for each node in order to assess the uncertainty of clinical endpoints.
2.3 Generative adversarial model
One way of studying probability distributions is by means of generative models, which describe the random phenomenon
in terms of the joint probability distribution of observed and target variables [48]. Generative adversarial networks
(GANs) are a framework for estimating generative models via an adversarial process [35]. They are often described
as a two-player game in which both players are encouraged to improve. One player, the generator, creates samples
that are intended to be indistinguishable from the ones coming from a given data distribution. The other player, the
discriminator, learns to determine whether samples come from the fake distribution (fake samples) or the real data
distribution (real samples). Figure 2 shows the basic idea of generative adversarial networks. With respect to other
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generative models, they provide a general and flexible framework for the analysis of joint probability distributions. The
architecture itself allows a fine control of the data generation process and a high level of customisation, making them
suitable for a variety of experimental scenarios.
P (x is real)
D(x)Discriminator
xfakexreal
G(z) Generator
z ∼ pz Noise prior
Figure 2: Generative Adversarial Network framework. The generator G(z) receives a vector z sampled from a noise
prior distribution pz, and generates a synthetic sample xfake. The discriminator D(x) tries to distinguish real samples
from fake samples, producing the probability of x coming from the real data distribution. The competition between the
two players drives the game and makes both players increasingly better.
2.3.1 Crosstalk between tissue-types
The activity of biological systems is determined by internal factors, determined by intrinsic and functional properties,
and by external factors shaping the interconnections between different systems. Chemical and molecular events,
like oxygenation or protein phosphorylation, are often the vehicles of biological signals’ transduction. A chain of
biochemical events forms a signalling pathway whose activation may give rise to a biochemical cascade of events
affecting the organism at different levels. In complex organisms several signal transduction pathways communicate and
react reciprocally generating biological crosstalks. Crosstalks have been widely characterised and observed in a variety
of biological processes from micro to macroscale from genomics [49, 50], to internal and external cell activity [51, 52],
and even between tissues [53]. Here, we develop a generative model based on a generative adversarial network to
produce synthetic transcriptomics data describing the ripple effects of a viral infection on crosstalks between different
tissues. The aim is to demonstrate how generative approaches can be used both to reproduce and enhance the set of
observable states of a patient allowing for a deeper understanding of complex biological processes.
Model. Consider a dataset D = {(x,m, r,q)} of samples from an unknown distribution Px,m,r,q, where x ∈ Rt×n
represents a vector of a patient’s gene expression values in t tissues; n is the number of genes; m ∈ {0, 1}t is a mask
vector indicating whether the expression of each tissue has been measured for the given patient; and r ∈ Rk and q ∈ Nc
are vectors of k quantitative covariates (e.g. age) and c categorical (e.g. gender), respectively. Our goal is to produce
realistic gene expression samples by modelling the conditional probability distribution P(X = x|M = m,R = r,Q =
q), where r includes the expression of ACE2 in different tissues (e.g. lung, kidney, and pancreas). By modelling this
distribution, we can sample data for different conditions and quantify the uncertainty of the generated expression values.
Our method builds on a Wasserstein GAN with gradient penalty (WGAN-GP) [54, 55]. Similar to Generative Adversarial
Networks (GAN) [35], WGAN-GPs estimate a generative model via an adversarial process driven by the competition
between two players, the generator and the critic.
The generator aims at producing samples from the conditional P(X|M,R,Q). Formally, we define the generator as a
function Gθ : Ru × Rk × Nc → Rt×n parametrised by θ that generates gene expression values xˆ as follows:
xˆ = mGθ(z, r,q) (7)
where z ∈ Ru is a vector sampled from a fixed noise distribution Pz and u is a user-definable hyperparameter. We apply
the mask m element-wise to match the distribution of missing tissues of the training dataset.
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The critic takes gene expression samples x from two input streams (the generator and the data distribution) and attempts
to distinguish the true input source. Formally, the critic is a function Dω : Rt×n×{0, 1}t×Rk×Nc → R parametrised
by ω that we define as follows:
y¯ = Dω(x¯,m, r,q)
where the output y¯ is an unbounded scalar that quantifies the degree of realism of an input sample x¯ given the covariates
r and q (e.g. high values correspond to real samples and low values correspond to fake samples). When the expression
of a certain tissue is unavailable for a given patient, we impute the unobserved values of x¯ with zeroes and set the
corresponding value of the mask m to zero.
We optimise the generator and the critic adversarially. Following [54], we train the generator Gθ and the critic Dω to
solve the following minimax game based on the Wasserstein distance:
min
θ
max
ω
E
x,m,r,q∼Px,r,q
[
Dω(x,m, r,q)− E
z∼Pz
[Dω(xˆ,m, r,q)]
]
subject to ||Dω(xi,m, r,q)−Dω(xj ,m, r,q)|| ≤ ||xi − xj ||
∀xi,xj ∈ Rt×n,m ∈ {0, 1}t, r ∈ Rk,q ∈ Nc
(8)
where xˆ is defined as in Equation 7 and the constraint enforces the critic Dω to be 1-Lipschitz, that is, the norm of the
critic’s gradient with respect to x must be at most 1 everywhere.
Let {(xi,mi, ri,qi)}bi=1 be a mini-batch of b independent samples from the training dataset D. Let {z1, z2, ..., zk}
be a set of k vectors sampled independently from the noise distribution Pz and let us define the synthetic samples
corresponding to the mini-batch as xˆi = mi Gθ(zi, ri,qi) for each i in [1, 2, ..., k]. We solve the minimax problem
described in Equation 8 by interleaving mini-batch gradient updates for the generator and the critic, optimising the
following problems:
Generator: min
θ
−1
k
k∑
i=1
Dω
(
xˆi,mi, ri,qi
)
Critic: min
ω
1
k
k∑
i=1
Dω
(
xˆi,mi, ri,qi
)−Dω(xi,mi, ri,qi)
+
λ
k
k∑
i=1
(||∇x˜iDω(x˜i,mi, ri,qi)||2 − 1)2
(9)
where λ is a user-definable hyperparameter and each x˜i is a random point along the straight line that connects xi and xˆi,
that is, x˜i = αixi + (1−αi)xˆi with αi ∼ U(0, 1). Intuitively, since enforcing the 1-Lipschitz constraint everywhere is
intractable (see Equation 8), the second term of the critic problem is a relaxed version of the constraint that penalises
the gradient norm along points in the straight lines that connect real and synthetic samples [55].
Architecture. Figure 1 shows the architecture of both players. The generator G receives a noise vector z as input
(green box) as well as sample covariates r and q (orange boxes) and produces a vector xˆ of synthetic expression values
(red box). The critic D takes either a real gene expression sample x (blue box) or a synthetic sample xˆ (red box), in
addition to sample covariates r and q, and attempts to distinguish whether the input sample is real or fake. For both
players, we use word embeddings [56] to model the sample covariates (light green boxes), a distinctive feature that
allows to learn distributed, dense representations for the different tissue types and, more generally, for all the categorical
covariates q ∈ Nc.
Formally, let qj be a categorical covariate (e.g. tissue type) with vocabulary size vj , that is, qj ∈ {1, 2, ..., vj},
where each value in the vocabulary {1, 2, ..., vj} represents a different category (e.g. whole blood or kidney). Let
q¯j ∈ {0, 1}vj be a one-hot vector such that q¯jk = 1 if qj = k and q¯jk = 0 otherwise. Let dj be the dimensionality of
the embeddings for covariate j. We obtain a vector of embeddings ej ∈ Rdj as follows:
ej = Wjq¯j
where each Wj ∈ Rdj×vj is a matrix of learnable weights. Essentially, this operation describes a lookup search in a
dictionary with vj entries, where each entry contains a learnable dj-dimensional vector of embeddings that characterises
each of the possible values that qj can take. To obtain a global collection of embeddings e, we concatenate all the
vectors ej for each categorical covariate j:
e =
∥∥∥c
j=1
ej
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where c is the number of categorical covariates and ‖ represents the concatenation operator. We then use the learnable
embeddings e in downstream tasks.
In terms of the player’s architecture, we model both the generator G and discriminator D as neural networks that
leverage independent instances eG and eD of the categorical embeddings for their corresponding downstream tasks.
Specifically, we model the two players as follows:
Gθ(z, r,q) = MLP(z‖r‖eG) Dω(x¯,m, r,q) = MLP(x¯‖m‖r‖eD)
where MLP denotes a multilayer perceptron.
3 Simulations
3.1 Clinical case studies
The clinical case studies used for the simulations are derived from [18]. The first scenario consists of an elderly patient
experiencing hypertension and type 2 diabetes with diabetic nephropathy. Her lifestyle is mainly sedentary and her
diet is rich in carbohydrates. The patient needs a therapeutic plan for the treatment of her hypertension. The task for
the clinician is to personalise the therapy according assigning a proper daily dosage of Benazepril. This case study is
used to show how the digital patient model can be employed to simulate the evolution over time of clinical endpoints
under a set of possible therapeutic plans and to choose the best option. In the second scenario the same patient is
seeking medical help for a mild flu caused by a SARS-CoV infection. For this case study the model can be used to
constantly monitor and forecast clinical endpoints to prevent complications threatening patient’s life. The decreased
oxygenation caused by flu may have detrimental effects on both heart and brain activities indeed. Studies have reported
that SARS-CoV infections can activate the blood clotting pathway by impairing left heart pumping performance which
results in a blood back up in the lungs and in a increased blood pressure. High blood pressure can reduce blood vessel’s
compliance decreasing blood and oxygen flows and leading to a higher risk of developing systemic conditions. For this
reason heparin-based therapies have been recommended to prevent clot formation or tissue plasminogen activator (tPA)
[57, 58]. Although some variation in blood pressure throughout the day is normal, a high blood pressure variability is
associated with a higher risk of cardiovascular disease [59, 60, 61, 62, 63] and all-cause mortality [64, 65]. Clogged
arteries, fibrosis, and strokes caused by blood pressure spikes are among the main complications threatening patient’s
life and calling for the foremost necessity for treatment. Hence, blood pressure is one of the most relevant clinical
endpoints which need to be constantly monitored in real time and accurately forecast.
3.2 Forecasting clinical scenarios and interpreting GNN simulations
The proposed GNN-based model presented in Section 2 is hereby used to actively monitor and forecast the endpoints
highlighted in the two clinical case studies. First, the computational ODE-based system described in [18] is used to
generate a time series for each differential equation with a window size of τ = 500 time steps [66]. Time series are
collected, randomly shuffled, and stacked in a dataset. Each item of the collection is randomly assigned either to a
training (ntrain = 3200), validation (nval = 800), or test set (ntest = 1000).
The graph model is derived from the structure of ODE system, thus leveraging human knowledge. Nodes correspond to
variables represented by the differential equations in [18] while edges follow the underlying relationships. In a GNN-
based model, each node learns a latent representation of the state using the messages received from its neighbourhood.
Hence, the rigid mathematical structure of the ODE system is relaxed in our model as such structure can be learned
directly from data. The learning process lasts for η = 50 epochs with a learning rate of  = 0.01. Once trained and
validated, the model is used to generate a bundle of possible trajectories for elements of the test set using the procedure
described in Section 2.2.4. As a result, the model estimates a 95% confidence interval of the evolution of each variable
over time.
Providing a complete overview of the clinical state of a patient is not trivial. Arguably, focusing just on one endpoint
might be misleading. On the contrary, a global vision comprising pathophysiological conditions is required in order to
provide a clear and effective overview where organs and physiological systems can be monitored as a whole. One of the
most effective approaches consists in applying a dimensionality reduction technique [67] condensing the information of
each organ and projecting forecasts in a lower-dimensional space. Figure 3 shows an overview of the clinical state of
the heart in a two-dimensional phase space. For each clinical case study, a GNN-based model is used to simulate a
therapeutic intervention and its impact on blood pressure in heart chambers (right and left atrium and ventricle). In order
to provide an overview of heart conditions, we projected the predicted trajectories using principle component analysis
(PCA, [68]). The interpretation of both pictures is straightforward. The first one shows the effect of a therapeutic
intervention comprising an increased physical exercise, a reduced amount of calorie intake, and the subscription of
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Figure 3: Two clinical case studies represented in a projected heart phase-space. The first case study (left figure) shows
the effect of a therapeutic intervention comprising an increased physical exercise, a reduced amount of calorie intake,
and the subscription of a daily dosage of Benazepril (5mg). The second simulation (right figure) shows the long-term
impact on blood pressure of an untreated SARS-CoV-2 infection (red density) and the effects of a therapy including
both Benazepril (5 mg/day) and intra venous injection of heparin (5000 U/ml) (orange density). [top figures] Bundle of
predicted trajectories can be visualised and monitored in real time in order to investigate patterns in the time domain.
The simulation shows blood pressure in heart chambers starting from healthy state conditions. Error bands represent
95% CI. [bottom figures]
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a daily dosage of Benazepril (5mg). The predicted result of the prescription (green density reporting the 95% CI of
the trajectories) reveals an overall reduction of blood pressure mean and variability in heart chambers. This results
in a reduced risk of developing severe cardiovascular conditions with detrimental ripple effects for the whole system.
The second figure, instead, reports the simulation corresponding to the second case study. The same patient is seeking
medical help to treat the first symptoms of a SARS-CoV-2 infection. The first simulation (red density) shows the
long-term impact on heart blood pressure of an untreated viral infection. In this case, blood pressure spikes may cause
irreparable damages to blood vessel walls, reducing their compliance, and impairing their capacity for adaptation to
different environmental conditions. A synergic therapy including both Benazepril (5 mg/day) and intra venous injection
of heparin (5000 U/ml) may have a beneficial effect on blood pressure mean and variability (orange density). On one
side, Benazapril lowers blood pressure by inhibiting ACE activity in cleaving ANG-I and producing ANG-II which is
the key RAS regulator of blood pressure. On the other hand, heparin is used to prevent and dissolve blood clots [57, 58].
The treatment has an indirect impact on blood pressure by making blood less dense, reducing clotting formation, and
lowering inflammation.
A lower-dimensional representation of an organ or system as a whole could be interesting to get a rapid and clear
overview of the long-term impact of a disease or a therapeutic intervention. Nonetheless, bundle of predicted trajectories
can be visualised and monitored individually in real time when needed in order to investigate patterns in the time
domain. Figure 3 shows an example where blood pressure trajectories in heart chambers are predicted in real time
starting from a healthy state condition (green density). In some cases, this representation in the time domain might be
closer to common clinical approaches, thus providing a more conventional visualisation tool for monitoring clinical
endpoints in real-time.
3.3 Transcriptomics analysis of the crosstalk between tissue-types
We hypothesise that the communication factors in blood might be playing an important role in the development of the
SARS-CoV-2 infection by facilitating the spread of the virus in the human body. Here, we study whether the expression
of genes involved in the renin-angiotensin system can be explained by genes that take part of the communicome in
blood. This analysis might shed light on whether it is sensible to model the crosstalk between tissue types with a GNN
where tissue nodes communicate with each other through whole blood.
Dataset. We leverage data from the Genotype-Tissue Expression (GTEx) project (v8), a resource that has generated
a comprehensive collection of human transcriptome data in a diverse set of tissues [69]. The dataset contains 15,201
RNA-Seq samples collected from 49 tissues of 838 unique donors. We select genes based on expression thresholds
of ≥ 0.1 TPM in ≥ 20% of samples and ≥ 6 reads in ≥ 20% of samples. We normalise the read counts between
samples using the trimmed mean of M-values (TMM) normalisation method [70] and we inverse normal transform
the expression values for each gene. From all the donors, we select those that have gene expression measurements for
whole blood, yielding 670 unique individuals. We then match the patients’ whole blood samples with the corresponding
measurements in lung (418), cortex of kidney (62), pancreas (257), and left ventricle of heart (324). Finally, we use the
KEGG pathway database [71] to select genes from the renin-angiotensin system (hsa04614), chemokine (hsa04062),
TNF (hsa04668), and TGF-β (hsa04350) pathways.
Model. We model the expression of genes from the renin-angiotensin system in lung, kidney, pancreas, and
heart as a function of genes in the chemokine, TNF, and TGF-β pathways in blood. Let Y = (Y1, ..., Yn)> and
X = (X1, ..., Xm)
> be multivariate random variables representing the expression of the n genes in the renin-angiotensin
system and the m genes in the signalling pathways, respectively. Our model is based on ridge regression [72]:
Y = XW + 
where W ∈ Rm×n is a matrix of learnable weights and  ∈ Rn are the residuals. We optimise the following objective:
min
W
||Y −XW||22 + α||W||22
where α is a hyperparameter that controls the regularisation strength. We also tried non-linear models such as support
vector machines, Gaussian processes, and random forests, but they were not significantly better than ridge regresssion
according to our cross-validation scores.
Results. Figure 4 show the bootstrapped R2 scores for each gene in the renin-angiotensin system pathway in different
tissue types. These results show that the expression of some genes in the ACE2 pathway can be partially explained
by signalling genes from whole blood. Notably, the associations for the kidney (cortex) are weaker or nonexistent,
potentially because the data is limited for this tissue (62 samples) or because the biological associations are indeed
small. Overall, these results suggest that signalling pathways such as TNF, TGF-β, and chemokine might be playing an
important role in the development of the SARS-CoV-2 infection.
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Figure 5: Pairwise correlations between genes in the renin-angiotensin system pathway in lung for real (left) and
synthetic (right) data. The correlations in the lower and upper matrices are computed from samples with low (60
samples) and high (61 samples) ACE2 expression, respectively.
3.4 Generative model for transcriptomics data
The generative model developed in Section 2.3 is here used to produce synthetic transcriptomics data. By conditioning
on high expression of ACE2 in the lung, kidney, and pancreas, we aim to simulate the effects of SARS-CoV-2 infection
in the expression of genes involved in communicome and signalling pathways such as TNF, TGF-β and chemokines.
These pathways are implicated in many physiological and pathological processes including the regulation of blood
pressure and inflammatory processes, and has been hypothesised to play a central role in SARS-CoV-2 infection
[73, 74].
Dataset. We use data from the GTEx project and process it as described in Section 3.3.
Results. Figure 5 shows that the pairwise correlations between genes in the ACE2 pathway (lung) are well preserved
in the synthetic data. We observe that some genes in the renin-angiotensin system pathway (CTSA, AGTR2, NLN, and
PREP) that can be relatively well explained as a function of blood signalling factors (see Figure 4) are simultaneously
correlated with ACE2. This suggests that these genes might be playing an important role in the spread of SARS-CoV-2
in our body through blood. Figure 6 shows that it is possible to sample data for synthetic patients conditioned on
different levels of ACE2 expression in lung.
3.5 Software
All the code for the experiments has been implemented in Python 3, relying upon open-source libraries [75, 76, 77]. All
the experiments have been run on the same machine: Intel R© CoreTM i7-8750H 6-Core Processor at 2.20 GHz equipped
with 8 GiB RAM. To enable code reuse, the Python code for the mathematical models including parameter values
and documentation is freely available under GNU Public License from a GitHub repository1 [78]. Unless required by
applicable law or agreed to in writing, software is distributed on an "as is" basis, without warranties or conditions of any
kind, either express or implied.
1https://github.com/pietrobarbiero/digital-patient
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Figure 6: Principal component analysis of the multi-tissue expression of 100 synthetic patients for different levels
of ACE2 expression. Each line corresponds to a unique patient. For each patient, we fix all the latent covariates and
modify the levels of ACE2 in lung. Overexpressing ACE2 leads to changes in the expression of other genes and these
changes follow a well-defined trajectory.
4 Discussion and conclusion
4.1 Interplay between GAN and GNN models
The models presented in this work (GAN, GNN) are independent of each other. On one hand, the main goal of the
GNN model (see Section 2.2) is to forecast various patient’s conditions based on real or synthetic data, integrating
information that spans multiple layers of the human body. On the other hand, the GAN model (see Section 2.3) is able
to generate data under different states, effectively enriching the space of pathophysiological conditions and endowing
the digital twin with the ability to simulate the effects of counterfactual events. The independence of these two models
enables a modular framework wherein each module can be trained separately on a distinct data modality. Importantly,
these modules can be composed and reused through transfer learning. In this work, we have shown how computational
models can be used to generate synthetic training data representing physiological conditions. Following the same
principles, each module of a complex architecture could be pre-trained on synthetic simulations, refined using data
obtained from horizontal population studies, and finally personalised according to clinical health records.
The GAN and the GNN models can be interconnected in a synergistic way. In order to train the GNN effectively, it
is necessary to have access to heterogenous, paired data modalities (from different layers: genomic, transcriptomic,
cellular, organ, exposomic, ...) collected from a comprehensive collection of patients and encompassing a wide variety
of conditions. However, to the best of our knowledge, to this date no such dataset exists. This is mainly because
collecting paired, multilayer data from patients is expensive and entails important ethical and privacy concerns [79, 80].
To address this issue, our GAN framework can synthesise data at multiple layers conditioned on the patient’s conditions
(e.g. diabetic, hypertension, ...) and clinical information (e.g. heart rate, blood pressure, age, sex, ethnicity, exercise,
nutrition, ...). This synthetic data can be used to train the GNN and impute missing data modalities of real patients.
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4.2 Advantages, limitations and visions
The promise of artificial intelligence in medicine is to provide composite, panoramic views of individuals’ medical data;
to improve decision making; to avoid errors such as misdiagnosis and unnecessary procedures; to help in the ordering
and interpretation of appropriate tests; and to recommend treatment [81]. The future of medicine is already bound
to AI. Technological innovations are completely changing medicine perspectives expanding its horizons and moving
towards an holistic view of human beings. The destiny of the whole healthcare system depends on this radical paradigm
shift. Embracing AI innovations is just a technological prerequisite, the first step towards a total transformation of
how medicine currently works, is delivered, and perceived by patients. Thinking that AI will just and mainly improve
clinical decision making is wrong. AI may actually open the doors to completely new ways of investigating the human
body as a whole. The core and ultimate purpose of health will be developing preventative and personalised pathways
to well-being rather than delivering treatments. This does not mean that medicine will no longer be connected to
illness. On the contrary, the future foreseen is that AI will assist medicine in improving diagnosis and devising novel
therapeutic strategies to deliver more effective solutions. The current healthcare revolution will not take back all the
past technological advances, but it will show them under a new light.
Ethical repercussions will also be huge [79, 80]. The transition has begun, but it will call for deeper trans-disciplinary
research and a substantial technological innovation in a variety of research areas. Education will also play a key role in
changing lifestyle habits and the way health is perceived, communicated, and delivered [82]. From a clinical standpoint,
AI will support a plethora of different tasks from medical check up to personalised intervention strategies to contrast
ripple effects or to promote healthy habits. In non acute states, predictive inference will propose prevention plans for
comorbidity management, particularly in presence of multiple therapies [83].
Increasingly large amount of personal data will be collected to feed modular machine learning (ML) models organised
to address specific and personalised medical issues. Clinical endpoints will be constantly monitored, shared, and
compared in order to answer relevant research questions and to deliver the best possible service. A deeper understanding
and practice of modelling in medicine will produce better investigation of complex biological processes, and even new
ideas and better feedback into medicine. Modelling-based approaches combined with data-driven ML techniques will
progressively provide models with higher degree of interpretability and generalisation ability [84] which will make
evidence-based medicine even more accessible intensifying the involvement of patients in the decision making process.
Besides, for each individual both healthcare systems and private companies will collect, save, and eventually exploit
an enormous amount of personal data. Providing an effective, stable, and unified juridical overview is critical on this
matter [85].
AI simulations forecasting the evolution of clinical endpoints over time will also reshape clinical guidelines [83] which
will no longer be based just on horizontal population studies. Cross-modality data will be collected for each patient and
machine learning models will be used to predict a bundle of possible trajectories representing the future states of the
patient allowing for personalised prescriptions, surgical planning and medical interventions. Finally, AI will change the
leading vehicle of medicine. The demand for AI-powered and IoT devices is increasing worldwide. The future medical
equipment will likely required to be cheap and extremely modular, but more importantly it needs to be deployable in
dedicated hardware to be distributed in larger markets.
The most important question around the integration of AI in medicine is about the benefit for the patient. A meaningful
quote about twins is the following: being a twin is like being born with a best friend. The data integration will make a
better portrait of patient’s condition trajectories but will require data inter-operability and data security. Technology is
often not neutral, but transformed to be biased in one way or another [86]. Individuals can have different unforeseen
readings and usage of new technologies. It may increase both user vulnerability and user empowerment. The
vulnerability is the combination of exposure to the variety of personal medical data and the coping capabilities of
users which could be different between young and mature people, as young are usually quicker in incorporating a new
technology into everyday life. The user is empowered if he/she acquires awareness and control of his/her condition and
context. A common example are online (website and blogs) initiatives such as patientslikeme which allow the user
to search and make up his/her mind about a disease [87]. Instead the user disempowerment depends on the lack of
technical knowledge of how mechanisms work; this is even enhanced in black box techniques such as deep learning.
The second question is about impact on how clinicians work or are trained. We believe that improving both data
integration and predictability will provide physicians with improved medical decisions support systems and a decrease
in both costs, through the evaluation of best therapies, and errors. A limitations is the poor interpretability and
explainability in deep learning architectures. This limitation will also greatly affect the training of the new clinicians on
AI technologies. There are growing efforts to make neural networks more interpretable in order to keep the human
(doctors and patients) in the loop. The interpretability could be improved by using in parallel mechanistic computational
modelling and simulations ([88, 89]), model extraction libraries (see for instance [90]), and visual inference tools [91].
This tool could also be complemented by clinical decision support systems such as [92].
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The complexly structured and multi level comorbidity and frailty patterns of most diseases describe a highly dynamical
system and are, therefore, challenging current medical therapies.
Mechanistic computational modelling and machine learning should be considered together when building innovative
healthcare solutions. Building a puzzle is often an example of participatory activity. Clinicians, mechanistic com-
putational modelling and machine learning researchers, data policy makers, public and private sectors could build a
puzzle (i.e. the healthcare) together and they should first develop a shared vision about what is the puzzle. Our vision
is to consider a co-simulation (say doctor checkup visits vs computational experiments) of the two twins to allow
co-verification. From a theoretical computer science perspective, this could open the direction of an interplay between
AI and verification/synthesis and the use of reachability analysis to identify constraints over the well-being and disease
system state space. Although different architectures seem suitable (e.g. only GNNs, only GANs, VAEs, etc), our design
has important advantages: the GNN could provide a physical mapping of the human body (in the same way a tube map
or bus route is a map of a city); GANs could be specialised on processing molecular information or they could operate
cross modal operations such as omic-omic, omic-clinical, clinical-clinical.
In this work we demonstrate the feasibility of representing and integrating physiological models and molecular
information using graph neural networks and generative adversarial networks. This composite approach provides
modularity and scalability across layers of biomedical data, it is amenable of a battery of modeling approaches, and
generates integrated predictions which translate into patients trajectories. We have assimilated our product to a digital
twin of the patient.
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